Identifiers
Hazards
Brands
1
Across 2 product types
Products
23
Product Types
2
Distinct formulation categories
Functions
0
Known functional-use labels
Product breadth indicates low commercial maturity. Only two commercial products exist, both from one brand, both launched in 2019, and both confined to facial care. This suggests minimal market adoption and limited category diversification. In contrast, the patent landscape shows substantial developmental activity across at least 70 patents spanning food, beverage, pharmaceutical, cosmetic, and agricultural applications, with recent publications through 2026. The gap between active patent development and sparse commercial product presence suggests the ingredient is in an early commercialization phase, with technology transfer and product launches still emerging.
Commercially, bacillus coagulans is positioned as a probiotic skin-care ingredient within a single brand's facial care line, with no evidence of broader market positioning. Patent evidence positions it far more expansively as a multifunctional probiotic with strain-specific benefits: blood glucose reduction, uric acid lowering, anti-aging and stress defense, intestinal flora regulation, physical performance enhancement, and metabolic health applications. The commercial positioning appears nascent and undifferentiated compared to the patent landscape, which emphasizes specific strain deposits and targeted health outcomes.
Ranked by number of tracked products that list bacillus coagulans, out of 23 total.
Commercial product evidence shows bacillus coagulans in only two facial care formats—a face wash and a face cream/moisturizer—both from a single brand and published in 2019. Patent evidence, however, reveals a much broader intended category range: probiotic powders, hypoglycemic products, microbial preparations, microcapsules, health supplement compositions, acidic beverages, probiotic-enriched fresh produce, sports nutrition compositions, hair loss treatments, and pharmaceutical compositions for obesity or diabetes. The commercial evidence is therefore narrow, while patent activity indicates the ingredient is being developed across food, beverage, pharmaceutical, cosmetic, and agricultural domains.
Tracked product categories ranked by distinct products containing this ingredient.
Recurring formulation patterns center on spore stability and delivery systems. Patents describe microencapsulation with inulin and xanthan gum, freeze-drying protectants containing skim milk powder, fructooligosaccharides, and monosodium glutamate, and spore-based formulations designed to survive brewing, acidic room-temperature storage, and colonization of fresh produce tissue. Co-ingredient patterns include prebiotic fibers such as fructooligosaccharides, galactooligosaccharides, inulin, and polydextrose, plus pairing with other probiotic strains like Lactobacillus and Bifidobacterium species. These patterns indicate a focus on viability preservation and synbiotic combinations rather than simple standalone supplementation.
Crowded patent spaces include metabolic health applications—blood glucose reduction, hypoglycemic effects, and α-glucosidase inhibition—with multiple patents covering similar strain-based approaches. Intestinal health and flora regulation also appear well represented. Differentiated spaces include polyamine-producing strains for hair growth and skin improvement, inactivated or dead bacillus coagulans for physical performance, spore-colonized fresh produce, and room-temperature acidic beverages with maintained spore viability. These less-crowded areas offer clearer differentiation opportunities, particularly where the mechanism extends beyond conventional probiotic activity.